Genelux Corporation
Company Details
Status: Public
Employees: 11-50
Location:
Westlake Village, California, United States of America
Type:
sample
Technology:
sample
sample
sample
About: Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer.
We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here.
For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux.
Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Genelux Corporation | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.